Literature DB >> 16402106

Neuropeptides and their receptors: innovative science providing novel therapeutic targets.

Susan D Brain1, Helen M Cox.   

Abstract

This review examines our current understanding of the roles of some of the best known neuropeptides that have played major roles in our combined research programmes. Evidence obtained from over 75 years of research shows involvement of these transmitters in a wide range of organs relevant to cardiovascular, respiratory, cutaneous, neuronal and intestinal systems. There is an increasing understanding of the mechanisms involved in the release of the peptides (substance P and calcitonin gene-related peptide (CGRP)) from sensory nerves or, neuropeptide Y (NPY) from sympathetic, parasympathetic and nonadrenergic, noncholinergic (NANC) neurons. Responses in target tissues result from interactions of the neuropeptides, or related forms, with specific G-protein coupled receptors (GPCRs or 7 transmembrane-spanning, 7TM proteins) that belong to either rhodopsin-like, class 1 (neurokinin (NK) and NPY Y receptors) or secretin-like, class 2 GPCRs (CGRP receptors). The majority of receptors activated by our chosen neuropeptides are now cloned, with knowledge of preferred agonists and selective antagonists for many receptor subtypes within these families. The study of neuropeptides in animal models has additionally revealed physiological and pathophysiological roles that in turn have led to the ongoing development of new drugs, through utilization predominantly of antagonist activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402106      PMCID: PMC1760747          DOI: 10.1038/sj.bjp.0706461

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype.

Authors:  Gavin A Bewick; James V Gardiner; Waljit S Dhillo; Aysha S Kent; Nicholas E White; Zoe Webster; Mohammad A Ghatei; Stephen R Bloom
Journal:  FASEB J       Date:  2005-08-11       Impact factor: 5.191

2.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

3.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors.

Authors:  Bouchaïb El Bahh; Silvia Balosso; Trevor Hamilton; Herbert Herzog; Annette G Beck-Sickinger; Günther Sperk; Donald R Gehlert; Annamaria Vezzani; William F Colmers
Journal:  Eur J Neurosci       Date:  2005-09       Impact factor: 3.386

5.  [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist.

Authors:  J Fuhlendorff; U Gether; L Aakerlund; N Langeland-Johansen; H Thøgersen; S G Melberg; U B Olsen; O Thastrup; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies.

Authors:  Yuan-Lin Dong; Kortney E Green; Sujatha Vegiragu; Gary D V Hankins; Elizabeth Martin; Madhu Chauhan; Chandrasekhar Thota; Chandrasekhar Yallampalli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-28       Impact factor: 5.958

7.  Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors.

Authors:  Alexandra Tschenett; Nicolas Singewald; Mirjana Carli; Claudia Balducci; Peter Salchner; Annamaria Vezzani; Herbert Herzog; Günther Sperk
Journal:  Eur J Neurosci       Date:  2003-07       Impact factor: 3.386

8.  Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin.

Authors:  J C Foreman; C C Jordan; P Oehme; H Renner
Journal:  J Physiol       Date:  1983-02       Impact factor: 5.182

9.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

10.  Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.

Authors:  R Mentlein; P Dahms; D Grandt; R Krüger
Journal:  Regul Pept       Date:  1993-12-10
View more
  53 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  A nociceptive signaling role for neuromedin B.

Authors:  Santosh K Mishra; Sarah Holzman; Mark A Hoon
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

Review 3.  Finding diamonds in the rubble.

Authors:  Jang-Ho J Cha
Journal:  Exp Neurol       Date:  2007-02-20       Impact factor: 5.330

Review 4.  [Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine].

Authors:  K Messlinger; M J M Fischer; J K Lennerz
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

5.  Efficient production of membrane-integrated and detergent-soluble G protein-coupled receptors in Escherichia coli.

Authors:  A James Link; Georgios Skretas; Eva-Maria Strauch; Nandini S Chari; George Georgiou
Journal:  Protein Sci       Date:  2008-07-01       Impact factor: 6.725

6.  Neuropeptide Y Y1 receptor effects on pulpal nociceptors.

Authors:  J L Gibbs; K M Hargreaves
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

Review 7.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 8.  Substance P in heart failure: the good and the bad.

Authors:  Heather M Dehlin; Scott P Levick
Journal:  Int J Cardiol       Date:  2013-11-12       Impact factor: 4.164

9.  Targeted disruption of the galanin gene attenuates inflammatory responses in murine skin.

Authors:  Sabine M Schmidhuber; Anna Starr; David Wynick; Barbara Kofler; Susan D Brain
Journal:  J Mol Neurosci       Date:  2007-11-13       Impact factor: 3.444

10.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.